Synapse - Works

Results (4640)

Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology/RTOG 1010

Meeting Abstract

Ilson, D.; Moughan, J.; Safran, H.; Wigle, D.; Depetrillo, T.; Haddock, M.; Hong, T.; Leichman, L.; Rajdev, L.; Resnick, M.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma

Meeting Abstract

Sangro, B.; Park, J.; Finn, R.; Cheng, A.; Mathurin, P.; Edeline, J.; Kudo, M.; Han, K.; Harding, J.; Merle, P.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

Outcomes for patients with advanced hepatocellular carcinoma and Child-Pugh B liver function in the phase 3 CELESTIAL study of cabozantinib vs placebo

Meeting Abstract

El-Khoueiry, A.; Meyer, T.; Cheng, A.; Rimassa, L.; Sen, S.; Milwee, S.; Kelley, R.; Abou-Alfa, G.
Annals of Oncology (2020)

Fulltext@MSK | Save

Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer (The BEACON CRC Study)

Meeting Abstract

Velez, L.; Trevino, T.; Kopetz, S.; Grothey, A.; Yaeger, R.; Gollerkeri, A.; Maharry, K.; Tabernero, J.
Annals of Oncology (2020)

Fulltext@MSK | Save

The novel regimen of tremelimumab in combination with durvalumab provides a favorable safety profile and clinical activity for patients with advanced hepatocellular carcinoma

Meeting Abstract

Kelley, R.; Kudo, M.; Harris, W.; Ikeda, M.; Okusaka, T.; Kang, Y.; Qin, S.; Tai, D.; Lim, H.; Yau, T.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

Efficacy of second-line chemotherapy in patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions: A retrospective analysis

Meeting Abstract

Javle, M.; Sadeghi, S.; Roychowdhury, S.; El-Khoueiry, A.; Goyal, L.; Philip, P.; Kelley, R.; Borbath, I.; Macarulla, T.; Yong, W.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

Infigratinib versus gemcitabine plus cisplatin as first-line therapy in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: phase 3 PROOF trial

Meeting Abstract

Abou-Alfa, G.; Borbath, I.; Cohn, A.; Goyal, L.; Lamarca, A.; Macarulla, T.; Oh, D.; Roychowdhury, S.; Sadeghi, S.; Shroff, R.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

Maintenance olaparib in patients aged ≥65 years with a germline BRCA mutation and metastatic pancreatic cancer: Phase III POLO trial

Meeting Abstract

Kindler, H.; Hammel, P.; Reni, M.; Van Cutsem, E.; Macarulla, T.; Hall, M.; Park, J.; Hochhauser, D.; Arnold, D.; Oh, D.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

A first-in-human phase Ia/b, open-label, multicentre, dose-escalation study of BI 905711 in patients with advanced gastrointestinal cancers

Meeting Abstract

Harding, J.; Hofheinz, R.; Elez, E.; Kuboki, Y.; Geng, J.; Schmohl, M.; Dowling, E.; Feng, Y.; Rasco, D.
Annals of Oncology (2020)

Fulltext@MSK | Save

KEYNOTE-859: A randomized, double-blind, placebo-controlled phase 3 trial of first-line pembrolizumab plus chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma

Meeting Abstract

Tabernero, J.; Bang, Y.; Van Cutsem, E.; Fuchs, C.; Janjigian, Y.; Bhagia, P.; Li, K.; Adelberg, D.; Qin, S.
Annals of Oncology (2020)

Fulltext@MSK | Save